Aristeia Capital’s Ibere Pharmaceuticals IBER Stock Holding History

Aristeia Capital’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-675,173	Closed	-$6.81M	–	518
2022 Q4	$6.81M	Buy	675,173 +250,000	+59%	+$2.5M	0.14%	189
2022 Q3	$4.21M	Buy	425,173 +75,000	+21%	+$740K	0.07%	309
2022 Q2	$3.44M	Buy	350,173 +173	+0%	+$1.7K	0.06%	322
2022 Q1	$3.43M	Buy	+350,000	New	+$3.41M	0.06%	314

Aristeia Capital's IBER Position: Q1 2023 in Review

Aristeia Capital sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 675,173 shares — an estimated $6.81M sold.

Aristeia Capital first reported a position in IBER in Q1 2022 and held it in 4 quarters. The position peaked at $6.81M in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Aristeia Capital reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Aristeia Capital sold 675,173 Ibere Pharmaceuticals shares in Q1 2023, an estimated $6.81M.
Aristeia Capital first reported a position in Ibere Pharmaceuticals in Q1 2022 and held it in 4 quarters.
Aristeia Capital's Ibere Pharmaceuticals position peaked at $6.81M in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Aristeia Capital's 13F filing for Q1 2023, filed 16 May 2023.